ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EPCLUSA
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EPCLUSA Rx

Generic Name and Formulations:
Sofosbuvir, velpatasvir 400mg/100mg; tabs.

Company:
Gilead Sciences, Inc.

Therapeutic Use:

Indications for EPCLUSA:

Chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection in adults without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin (RBV).

Adult:

Test for HBV infection prior to initiation. 1 tab once daily. Without cirrhosis or with compensated cirrhosis (Child-Pugh A): treat for 12 weeks. With decompensated cirrhosis (Child-Pugh B or C): treat with RBV for 12 weeks. HCV/HIV-1 co-infection: follow same dosage schedule.

Children:

<18yrs: not established.

Contraindications:

When co-administered with ribavirin, its contraindications also apply to this combination regimen (eg, Pregnancy Cat.X).

Warnings/Precautions:

Risk of HBV reactivation in patients coinfected with HCV/HBV. Test all patients for HBV infection by measuring HBsAg and anti-HBc; if positive serologic evidence, monitor for hepatitis flare or HBV reactivation during and at post-treatment follow-up; treat if clinically indicated. Increased risk of symptomatic bradycardia when concomitant amiodarone esp. patients also taking beta-blockers or with cardiac comorbidities and/or advanced liver disease. Severe renal impairment (eGFR <30mL/min/1.73m2) or ESRD requiring hemodialysis. Pregnancy. Nursing mothers.

Interactions:

Concomitant amiodarone: not recommended; if no alternatives, monitor cardiac function (see full labeling). Concomitant certain immunosuppressants or chemotherapeutic agents: may increase risk of HBV reactivation. May potentiate P-gp, BCRP, OATP1B1, OATP1B3, or OATP2B1 substrates. Concomitant P-gp and/or moderate to potent CYP2B6, CYP2C8, CYP3A4 inducers (eg, rifampin, St. John’s wort, carbamazepine), anticonvulsants (eg, phenytoin, phenobarbital, oxcarbazepine), rifabutin, rifapentine, tipranavir/ritonavir, topotecan, efavirenz-containing regimens: not recommended. Separate dosing of antacids by 4hrs. May give H2-antagonists simultaneously or 12hrs apart (comparable to max famotidine 40mg twice daily). Concomitant omeprazole or other PPIs: not recommended; if necessary, take Epclusa with food 4hrs before omeprazole 20mg. May potentiate digoxin; monitor. Concomitant tenofovir DF regimens; monitor. May potentiate rosuvastatin (do not exceed 10mg dose) and atorvastatin (monitor).

Pharmacological Class:

HCV NS5B polymerase inhibitor + HCV NS5A inhibitor.

Adverse Reactions:

Headache, fatigue, nausea, asthenia, insomnia; with ribavirin: anemia, diarrhea.

Note:

For ribavirin specific dosing and safety information, refer to the full prescribing information.

Generic Availability:

NO

How Supplied:

Tabs—28

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs